The effect of statins on psoriasis severity: a meta-analysis of randomized clinical trials
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Introduction: Statins may reduce the severity of psoriasis, but the available evidence is unclear.We conducted a meta-analysis of randomized controlled studies (RCTs) that investigated the effect of statins on psoriasis severity assessed with the Psoriasis Area and Severity Index (PASI).Material and methods: Two investigators searched independently the following databases: Medline, EMBASE, Cochrane Central Register of Controlled Trials and ClinicalTrials.govfrom inception to February 2019.Additionally, reference lists from all available articles were searched manually.We included only RCTs carried out among adult (≥ 16 years) patients with psoriasis who received oral statins for ≥ 8 weeks and had psoriasis severity assessed with the PASI at baseline and at the end of follow-up.We used random effects meta-analysis to calculate the mean difference (D) in PASI change between patients who received either a statin or a comparator.Results: Of 279 records identified, there were 5 eligible RCTs, with a total of 223 patients, including 128 patients who received a statin (atorvastatin or simvastatin).The improvement in psoriasis severity (PASI) was significantly greater in patients who received statins than in those who received comparators (D = 2.76, 95% CI: 0.49-5.04,p = 0.017).In subgroup analyses, the improvement in PASI values was significant for simvastatin (D = 3.70, 95% CI: 2.52-4.89,p < 0.001) but not for atorvastatin (D = 2.30, 95% CI: -1.28-5.88,p = 0.210).Conclusions: Oral statins may improve psoriasis, particularly in patients with severe disease.This observation should be verified in long-term, well-designed studies that will enable analyses adjusted for clinical variables.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Barylski, M., Nikfar, S., Mikhailidis, D. P., Toth, P. P., Salari, P., Ray, K. K., Pencina, M. J., Rizzo, M., Rysz, J., Abdollahi, M., et al. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.03.007 · Cited by 98 · cited 1×
“Arch Med Sci 1, December / 2019 5 patients [30, 31].”
BackgroundEfficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
Rysz-Górzynska, M., Gluba-Brzózka, A., Sahebkar, A., Serban, M.-C., Mikhailidis, D. P., Ursoniu, S., Toth, P. P., Bittner, V., Watts, G. F., Lip, G. Y. H., et al. (2016) · Scientific Reports · doi:10.1038/srep30060 · Cited by 33 · cited 1×
“The results of selected meta-analyses indicate no significant effect of statin therapy on pulmonary arterial hypertension and blood pressure in normotensive and hypertensive subjects [28, 29].”
Cited by
Krishnamoorthy, Y., Nagarajan, R., Saya, G. K., & Menon, V. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113382 · Cited by 550
Myrcene—What Are the Potential Health Benefits of This Flavouring and Aroma Agent?
Surendran, S., Qassadi, F., Surendran, G., Lilley, D., & Heinrich, M. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.699666 · Cited by 254
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
Møller, L. B. P., Kromann, B., Kabatnik, S., Hjortlund, J. H., Haulrig, M. B., Sølberg, J. B. K., Bzorek, M., Clark, R. A., Skov, L., Mann, M., et al. (2025) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2025.05.002 · Cited by 12
Metadata
- Authors
- Socha, M., Pietrzak, A., Grywalska, E., Pietrzak, D., Matosiuk, D., Kiciński, P., & Rolinski, J.
- Venue
- Archives of Medical Science
- Publisher
- Termedia Sp. z.o.o.
- Published
- 2020
- Volume
- 16
- Issue
- 1
- Pages
- 1-7
- ISSN
- 1734-1922 (ISSN-L)
- OpenAlex
- W2998982231
- Cited by
- 59
- References
- 3
- FWCI
- 0.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.